RCKT Stock Forecast: Rocket Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.95
−7.58% on the day

The median 12-month analyst price target for Rocket Pharmaceuticals, Inc. is $9.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$235.6M
Ticker Nerd rank
36/ 100
Median analyst target
$9.50
Analysts covering
14
Revenue$0.0
Operating income−$46.9M
Net income$123.2M
Free cash flow−$39.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.2%
1M
−16.7%
YTD
−44.4%
1Y
−31.3%
From 52W high
−63.2%
From 52W low
0.0%
$1.95
$5.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Rocket Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
36/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Quality
62
Volatility
48
Value
41
Momentum
39
Revisions
34
Accruals
29
Issuance
19

Growth (82): Sales and profits are climbing, and climbing faster than before.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RCKT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RCKT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26RCKTHigh $15.00Median $9.50Low $2.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
7
Buy
6
Hold
1
Sell
$2.75
Low
$9.50
Median
$15.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
17 Nov 2026Chardan CapitalMaintainsBuy$11
8 Oct 2026Goldman SachsUpgradeNeutral$3.00 → $4.00
7 Oct 2026Chardan CapitalMaintainsBuy$11
7 Oct 2026Leerink PartnersMaintainsMarket Perform$7.00 → $4.00
7 Oct 2026WedbushReiteratesOutperform$15
16 Sept 2026NeedhamUpgradeBuy$9.00
16 Sept 2026WedbushReiteratesOutperform$15
15 Sept 2026Chardan CapitalMaintainsBuy$11
1 Sept 2026Chardan CapitalMaintainsBuy$11
11 Aug 2026WedbushMaintainsOutperform$16 → $15
11 May 2026Chardan CapitalMaintainsBuy$11
30 Mar 2026B of A SecuritiesMaintainsBuy—
27 Mar 2026Chardan CapitalMaintainsBuy—
2 Mar 2026Goldman SachsMaintainsSell—
27 Feb 2026Cantor FitzgeraldMaintainsOverweight—
18 Nov 2025B of A SecuritiesMaintainsBuy—
18 Nov 2025JP MorganDowngradeUnderweight—
14 Oct 2025Chardan CapitalMaintainsBuy—
3 Oct 2025Leerink PartnersMaintainsMarket Perform—
20 Aug 2025B of A SecuritiesUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RCKT.

Market Radar

This page is one stock. Monday covers all of them.

RCKT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RCKT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Rocket Pharmaceuticals, Inc. returned −31.3% against +6.9% for the S&P 500, dividends included.

RCKT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26RCKTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RCKT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−5.0%

Higher than 40% of US stocks

Return on assets
−30.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rocket Pharmaceuticals, Inc. has a market value of $235.6M and an enterprise value of $21.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$17.3M.

  • Diluted earnings per share, trailing twelve months: −$0.17.

  • Free cash flow in the twelve months to 30 June 2026: −$170.4M.

  • Shares outstanding: 109.5M.

  • Rocket Pharmaceuticals, Inc. employs 202 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

RCKT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RCKTRocket Pharmaceuticals, Inc.$235.6M36
ARCTArcturus Therapeutics Holdings, Inc.$211.7M74
IPSCCentury Therapeutics, Inc.$209.3M44
ALLOAllogene Therapeutics, Inc.$207.9M45
PYXSPyxis Oncology, Inc.$216.2M74
DTILPrecision BioSciences, Inc.$204.3M81
KROSKeros Therapeutics, Inc.$218.5M83

Take a look at RCKT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Rocket Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RCKT

What is the RCKT stock price forecast for 2026-2027?

The median 12-month analyst price target for Rocket Pharmaceuticals, Inc. is $9.5, with estimates ranging from $2.75 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RCKT stock a buy right now?

Of the 14 analysts covering Rocket Pharmaceuticals, Inc., 7 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Rocket Pharmaceuticals, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RCKT?

As at 21 Nov 2026, Rocket Pharmaceuticals, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will RCKT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts is $9.5, and Ticker Nerd's factor model ranks Rocket Pharmaceuticals, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RCKT stock forecast for 2030?

No analyst covering Rocket Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.75 to $15 over the next 12 months.

How has RCKT stock performed over the past year?

Rocket Pharmaceuticals, Inc. returned -31.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rocket Pharmaceuticals, Inc. do?

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions.

Company

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions. Rocket Pharmaceuticals currently develops and advances investigational and commercial genetic medicines, including therapies for disorders such as Danon disease, BAG3-related dilated cardiomyopathy, Fanconi anemia, and severe leukocyte adhesion deficiency-I. The company is also involved in manufacturing, clinical development, and the commercialization of its gene therapy products. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals plays a specialized role in the rare-disease market by targeting conditions with significant unmet medical need through precision genetic medicine.

CEO Dr. Gaurav D. Shah M.D. · 202 employees · United States · https://www.rocketpharma.com